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As the prevalence of osteoporosis is expected to increase over the next few 
decades, the development of novel therapeutic strategies to combat this disorder becomes 
clinically imperative.  These efforts draw extensively from an expanding body of 
knowledge pertaining to the physiologic mechanisms of skeletal homeostasis.  To this 
body of knowledge, we contribute that cells of hematopoietic lineage may play a crucial 
role in balancing osteoblastic bone formation against osteoclastic resorption.  
Specifically, our laboratory has previously demonstrated that megakaryocytes can induce 
osteoblast proliferation in vitro, but do so only when direct cell-to-cell contact is 
permitted.  To further investigate the nature of this interaction, we have effectively 
neutralized several adhesion molecules known to function in the analogous interaction of 
megakaryocytes with another cell-type of mesenchymal origin - the fibroblast.  Our 
findings implicate the involvement of fibronectin/RGD-binding integrins including α3β1 
(VLA-3) and α5β1 (VLA-5) as well as glycoprotein IIb (CD41), all of which are known to 
be expressed on megakaryocyte membranes.  Furthermore, we demonstrate that IL-3 can 
enhance megakaryocyte-induced osteoblast activation in vitro, as demonstrated in the 
megakaryocyte-fibroblast model system.  Taken together, these results suggest that 
although their physiologic and clinical implications are very different, these two models 
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Skeletal fragility has emerged as a major limitation to quality of life as we age. 
Osteoporosis currently affects approximately 10 million people in the United States 
alone; another 34 million Americans have low bone density, placing them at increased 
risk of the disease. Together, more than 55 percent of the population aged 50 years and 
older are affected or at risk of osteoporosis. The disease carries a significant financial 
burden. In 2005, osteoporosis-related fractures were responsible for approximately 19 
billion dollars in health care costs; this number is expected to increase to more than 25 
billion dollars by 2025. More importantly, osteoporosis and the ensuing hip, wrist, and 
vertebral fractures are significant sources of morbidity and pain among the elderly: such a 
fracture can be the sentinel event that transforms a relatively healthy, independent senior 
citizen into a person requiring significant assistance for daily living.  This downward 
spiral is evidenced by a one-year post-hip fracture mortality of 24 percent. Further, as 
many as 20 percent of individuals who were previously ambulatory require long-term 
care after a hip fracture (1). 
 
As the prevalence of osteoporosis is expected to increase over the next few 
decades, the development of novel therapeutic strategies to combat this development of 
this disorder becomes clinically imperative.  These efforts draw extensively from an 
expanding body of knowledge pertaining to the physiologic mechanisms of skeletal 
homeostasis.  To this body of knowledge, we contribute that cells of the hematopoietic 





Over the past decade, a new paradigm has emerged wherein megakaryocytes have 
been found to play a regulatory role in skeletal homeostasis.  Cumulatively, the data 
demonstrate that megakaryocytes may act to stimulate bone formation by expressing and 
secreting bone-related proteins to enhance osteoblastic proliferation and differentiation 
directly (2-10)  
 
Several bone-related proteins are produced or secreted by megakaryocytes to 
influence bone mineralization and catabolism. Osteocalcin is a bone matrix protein 
considered to be a marker of bone turnover. Previously, this protein was thought to be 
synthesized exclusively by osteoblasts at mineralizing surfaces; however, osteocalcin 
mRNA transcripts have been found to be enriched in platelet-producing megakaryocytes 
within peripheral blood. The levels of megakaryocyte-associated osteocalcin in blood 
increased during periods of rat growth, suggesting that megakaryocytes function in the 
regulation of bone remodeling and turnover. (2) 
.  
Osteonectin, a secreted calcium-binding glycoprotein, is a component of bone 
extracellular matrix. This protein binds extracellular matrix, via protein-protein 
interactions with type I collagen, to inhibit the growth of hydoxyapatite crystals, 
implicating osteonectin in the control of bone anabolism. While this glycoprotein is 
produced by both osteoblasts and megakaryocytes, the two forms of the protein differ in 
both complex glycosylation structure (3) and immunogenicity (4). Within platelets, 
osteonectin forms a calcium-dependent complex with the platelet-specific protein 




regulated production of this protein by megakaryocytes, its inclusion into platelets, and 
its unique associations within those cells again implicates a unique role for 
megakaryocytes and megakaryocyte-derived osteonectin in the regulation of bone growth 
(3).  
 
Bone sialoprotein is major component of bone and other mineralized tissues. 
While the function of this protein remains to be clarified, it has been hypothesized that 
this protein may function to nucleate apatite crystals during bone formation. This protein 
is also found within megakaryocytes and platelets (5), although it does not appear to be 
synthesized by these cells; instead it appears to be acquired by endocytosis, 
proteolytically processed, and stored in the alpha granules of platelets to be released upon 
platelet activation (11).  It is unclear if release of this protein by megakaryocytes or 
platelets plays a role in bone homeostasis, but megakaryocytes are again implicated in the 
overall regulation of bone mass.  
 
 Osteopontin, also known as secreted phosphoprotein 1 (SPP1), was originally 
isolated as a structural component of bone synthesized by osteoblasts.  Synthesis of this 
protein is enhanced by activated vitamin D.  Osteopontin is thought to act as a “bridge” 
anchoring osteoclasts to bone.  This protein has since been found to be expressed by 
multiple cell types, including bone marrow megakaryocytes (6). It has been hypothesized 
that megakaryocytes secrete factors that influence osteoblast activity, but that close 
proximity to bone stromal cells is required for this effect.  Expression of osteopontin by 




facilitating megakaryocyte function in bone mineralization. megakaryocytes express 
osteocalcin and secrete the bone matrix proteins osteonectin, osteopontin, and bone 
sialoprotein.   
 
 megakaryocytes also produce bone morphogenic proteins (BMPs); proteins that 
induce ectopic osteogenesis. BMP mRNA and proteins can be detected within both 
megakaryocytes and platelets by in situ hybridization and immunoblotting.(7) GATA-1- 
and NF-E2-deficient mice, which both display increased numbers of immature marrow 
megakaryocytes, exhibit increased BMP production and excessive bone formation with a 
200-300% increase in bone volume and growth parameters (8). GATA-1 and NF-E2 are 
transcription factors required for the normal differentiation of megakaryocytes.  Deficient 
animals exhibited normal osteoblast and osteoclast numbers and function.  However, the 
proliferation of osteoblasts wild-type and mutant, increased approximately six-fold upon 
co-culture with megakaryocytes from deficient mice (8). These results indicate that an 
interaction, either direct or indirect, between osteoblasts and megakaryocytes results in 
osteoblast proliferation and increased bone formation. Cultures of osteoblasts with 
conditioned medium from mutant megakaryocytes failed to produce this increase in 
osteoblast proliferation; direct contact between megakaryocytes and osteoblasts was 
required for this effect. Thus, direct contact between megakaryocytes and osteoblasts 
results in an increase in osteoblast proliferation, leading to increased bone mass. This 
finding may help explain the osteosclerosis observed in human patients with forms of 
myelongenous leukemias associated with increased numbers of marrow megakaryocytes 





 Such an interaction between osteoblasts and megakaryocytes is also supported by 
work from Miao et al. (9) examining osteoblast colony formation and alkaline 
phosphatase expression. Aggregates of bone marrow stromal cells, which contain 
megakaryocytes, formed large colonies expressing abundant alkaline phosphatase. When 
these aggregates were dissociated, allowing osteoblast precursors to grow as single-cell 
suspensions, colonies still formed, but were smaller and expressed only minimal amounts 
of alkaline phosphatase. These data suggest that removing the supportive influence of 
megakaryocytes reduces the osteoblastic differentiation of bone marrow stromal cells. 
Again, these results point to an interaction of osteoblasts with megakaryocytes to achieve 
maximal osteoblast differentiation and activity. 
 
 Our own laboratory has recently examined the role of gap junction intracellular 
communication (GJIC) between osteoblasts and megakaryocytes (45).  This work has 
demonstrated that megakaryocytes  and osteoblasts can communicate by GJIC and that 
GJIC may serve to inhibit megakaryocyte-mediated enhancement of osteoblast 
proliferation, but does not appear to alter megakaryocyte-mediated reductions in 
osteoblast differentiation. Additionally, megakaryocytes were observed to inhibit 
osteoblast differentiation when co-cultured for extended durations.   
 
 In addition to increasing osteoblast proliferation, megakaryocytes appear to 
influence osteoblastic activity. Osteoblast activity was assessed by measuring the 




formation activity, and RANKL, which is upregulated during bone remodeling and 
resorption. osteoblasts cultured with CD61-positive megakaryocytes exhibited increased 
intensity of type-I collagen expression over that seen by osteoblasts cultured alone or 
with control non-megakaryocytic cells. Co-culture with megakaryocytes also increased 
both the proportion of osteoblasts producing osteoprotegerin and the intensity of OPG 
expression by those cells. In addition, RANKL expression by osteoblasts was suppressed 
by co-culture with megakaryocytes.   
 
 Megakaryocytes can also produce OPG to influence osteoblastic and osteoclastic 
activity directly (13).  High levels of OPG mRNA are seen in both platelets and 
megakaryocytes.  Strong immunostaining for OPG could be seen in mature 
megakaryocytes. OPG staining in megakaryocytes was enhanced by treatment with 
thrombopoietin, a megakaryocyte-specific growth factor, indicating that megakaryocyte 
maturation correlates with increased OPG expression.  Thus, in addition to indirectly 
affecting osteoclast and osteoblast function, megakaryocytes can directly stimulate 
osteoblast differentiation and inhibit osteoclast function through the production of 
osteoprotegerin.  
 
Estrogen deficiency is well known to play a role in the pathogenesis of 
osteoporosis, resulting in increased bone resorption and bone loss.  Estrogen participates 
in the maintenance of bone mass and inhibits bone resorption. Estrogen therapy, although 
associated with other risks, is effective at increasing bone mass or at least stopping bone 




underlying mechanisms of these results.  The effect of estrogen on human osteoblast 
cultures was assessed by measuring factors involved in bone homeostasis. These data 
revealed that osteoblasts treated with estradiol exhibit a sustained increase in OPG 
expression at both 24 and 48 hours after stimulation. A significant increase in RANKL 
expression at 24 hours was also observed; however, this increase was not sustained at 48 
hours. These effects could be specifically inhibited with an estrogen antagonist. Thus, 
estrogen may exert an anti-resorptive effect on bone by stimulating the production of 
factors involved in bone anabolism in excess of catabolic factors (15).  The molecular 
mechanism underlying this effect is unclear, but may be mediated at least in part by 
interactions with megakaryocytes. The addition of estrogen to cultures of hematopoietic 
stem cells stimulates the colony-forming potential to a megakaryocytic phenotype, 
implicating megakaryocytes in estrogen-induced bone formation (16). In addition to 
encouraging megakaryocyte differentiation, estrogen significantly increased OPG 
expression and suppressed RANKL expression by megakaryocytes (17).  Thus, the 
function of estrogen in the maintenance of bone mass may be mediated, at least in part, 
by the stimulation of megakaryocytopoiesis and the upregulation of factors involved in 
bone formation and the downregulation of osteoclastogenesis.  
 
Simultaneously, megakaryocytes may regulate bone resorption by 
expressing/secreting several factors known to be involved in osteoclastogenesis, and 
recent studies demonstrate that megakaryocytes can inhibit osteoclast formation in vitro 
(13, 15-24).  Co-cultures of megakaryocytes with spleen cells from wild-type C57BL/6 




ample osteoclasts in the absence of megakaryocytes (24). This effect could be reproduced 
by the addition of conditioned media from megakaryocytes to spleen cell cultures, 
indicating that the inhibition of osteoclast development by megakaryocytes was mediated 
by a soluble factor. While osteoprotegrin, which is know to inhibit osteoclast 
proliferation, was present in megakaryocyte-conditioned media, this factor was not 
responsible for megakaryocyte-mediated growth inhibition, as conditioned media from 
OPG-deficient mice and conditioned media containing OPG-neutralizing antibodies were 
still able to inhibit osteoclastogenesis in vitro.  Similarly, neutralization of TGF-β, which 
was also present in conditioned media, was also unable to abrogate the growth inhibitory 
effect of megakaryocytes on osteoclasts (24).   
 
The role of megakaryocytes in bone growth and catabolism was confirmed by 
studies in mice deficient in p45 NF-E2, a key transcription factor required for 
megakaryocyte differentiation (25).  These mice are characterized by increased numbers 
of immature megakaryocytes and the absence of functional platelets.  As mentioned 
above, these animals display an increased bone mass, and increased bone formation rate.  
Increased bone formation, however, was only observed in sites of hematopoiesis, not in 
flat bones, such as calvariae, again confirming the role of megakaryocytes in bone 
homeostasis. This phenotype of increased bone mass and growth could be adoptively 
transferred into recipient irradiated wild-type mice with the hematopoietic cell 
population, again implicating megakaryocytes as the responsible cell lineage. The net 
result, as demonstrated in vivo, is that increases in megakaryocyte number lead to 





In attempting to identify molecules involved in the megakaryocyte-osteoblast 
interactions that regulate bone homeostasis, we look to the interactions of 
megakaryocytes with fibroblasts, another cell of mesenchymal origin.  Through 
examination of the pathogenesis of myelofibrosis, the molecular mechanisms underlying 
both the paracrine and direct cell-cell interactions of megakaryocytes with fibroblasts 
have been elucidated.  These mechanisms may represent a generalized mechanism by 
which megakaryocytes influence the function and proliferation of neighboring cells. 
 
Myelofibrosis, characterized by bone marrow fibrosis, extramedullary 
hematopoiesis, splenomegaly, and increased peripheral blood immature hematopoietic 
progenitors, is a secondary phenomenon that accompanies the clonal transformation of 
hematopoietic lineage cells in chronic myeloproliferative disorders.  In this disease, 
excessive fibroblast cell proliferation and increased secretion of matrix proteins, such as 
collagen and reticulin, reduces the ability of the bone marrow to produce functional cells, 
leading to bone marrow failure and multiple cytopenias.  The correlation of fiber density 
and megakaryocyte number first linked the reactive proliferation of fibroblasts in this 
condition to interactions with megakaryocytes (26).  In addition, mice given bone marrow 
grafts of cells infected with a retrovirus expressing exogenous thrombopoietin, the 
primary stimulator of megakaryocytopoiesis, develop a lethal myeloproliferative disorder 
resembling human idiopathic myelofibrosis (27).  Subsequent studies demonstrated that 
megakaryocytes could stimulate fibroblast proliferation (28).  Homogenates of 




cytokines and growth factors, such as platelet-derived growth factor (PDGF) and 
transforming growth factor-β (TGF-β) (22, 28).   Megakaryocyte-dependent growth 
promotion was effectively abrogated by neutralizing antibodies directed against these 
proteins, demonstrating the critical role of these growth factors in fibroblast proliferation 
(29).   
To determine additional cytokines that may function in the megakaryocyte-
dependent enhancement of fibroblast proliferation, Schmitz et al. examined the effect of a 
barrage of cytokines on fibroblasts and fibroblast-megakaryocyte co-cultures.  While 
many of these cytokines, such as IL-1, did not have any effect on fibroblast proliferation, 
recombinant human IL-3 (rhIL-3) significantly increased the number of fibroblasts in co-
cultures.  No enhancement of fibroblast proliferation could be detected with the addition 
of rhIL-3 in the absence of megakaryocytes, suggesting that IL-3 induced 
megakaryocytes to undergo changes that promoted fibroblast growth.  Interestingly, the 
effect of IL-3 could be inhibited by the addition of neutralizing antibodies against PDGF 
and TGF-β, suggesting that IL-3 stimulation of megakaryocytes induced the secretion of 
growth factors that enhanced fibroblast proliferation.  
 
For years, lymphocytes have been thought to be the major sources of cytokines 
within the bloodstream and the bone marrow. Substantial evidence, as detailed above, is 
now accumulating that megakaryocytes may produce a barrage of cytokines that 
influence both hematopoietic cells and surrounding stromal cells in autocrine and 
paracrine mechanisms. While the role of IL-3 in megakaryocyte-osteoblast interactions is 




soluble growth factors by megakaryocytes. Wickenhauser et al. (23) examined the effect 
of rhIL-3 on megakaryocyte activity by looking at the resulting stimulation of cytokine 
production. Following stimulation with IL-3, megakaryocytes demonstrated significantly 
increased production of IL-3 itself, granulocyte-macrophage colony stimulating factor 
(GM-CSF), and IL-6.  Likewise, TGF-β, whose production is also stimulated by IL-3 
treatment (22), upregulated megakaryocyte production of IL-6, IL-1, and GM-CSF (20). 
A megakaryocyte-like cell line, HU3, was shown to produce IL-1β, IL-6, IL-10, and 
TNF-α, while a bipotential progenitor-type cell line, MB02, did not. This secretion could 
be enhanced following treatment with thrombopoietin, indicating the association between 
cytokine secretion and megakaryocyte differentiation (21). Also, these factors also act in 
a positive feedback mechansism in concert with thrombopoietin to enhance 
megakaryocyte differentiation (30).  Estrogens have previously been shown to control the 
production of cytokines, such as IL-1 and IL-6, that modulate bone homeostasis  (31). 
These cytokines appear to act in both an autocrine fashion, acting as a positive feedback 
loop encouraging additional cytokine secretion by megakaryocytes, and a paracrine 
fashion, possibly acting on osteoblasts and osteoclasts to influence their proliferation and 
function.   
 
Despite substantial evidence implicating soluble factors such as cytokines in 
fibroblast proliferation, the addition of soluble factors alone to fibroblast cultures was 
unable to produce the substantial enhancement of fibroblast proliferation seen with intact 
megakaryocytes (32)  These results and the close proximity of fibroblasts and 




might be required for the enhancement of proliferation.  Indeed, in the cytokine studies 
detailed above, inhibition of cell-cell contact in both unstimulated and IL-3-stimulated 
cultures significantly impaired megakaryocyte-induced fibroblast proliferation (32). 
Using a transwell assay system, cell-cell contacts were inhibited via tissue culture inserts, 
generating a substantial impairment in fibroblast growth, even in the presence of IL-3 
(33).  Identification of the cell surface receptors functioning in fibroblast- megakaryocyte 
interactions may identify candidate molecules that may control the interactions of 
megakaryocytes with osteoblasts.  
 
Integrins are abundant cell-surface proteins that interact with both other cell 
surface receptors and components of the extracellular matrix. These proteins are also 
well-known to initiate multiple conserved signal transduction pathways that trigger cell 
activation and proliferation.  The α3β1 and α5β1 integrins were implicated in direct cell-
cell interactions utilizing blocking studies with specific anti-α3 and anti-α5 antibodies.  
Such antibodies not only inhibited the megakaryocyte-mediated enhancement of 
fibroblast proliferation, but significantly disrupted megakaryocyte attachment to the 
adherent fibroblast monolayer (34).  β1-containing integrins bind to fibronectin through 
recognition of a conserved peptide sequence of Asp-Gly-Asp (RGD). Addition of a 
soluble oligomer, Asp-Gly-Asp-Ser (RGDS), interferes with this interaction, blocking the 
interaction of β1 integrins with their substrates.  Megakaryocyte-associated fibroblast 
proliferation, although not adhesion, was significantly inhibited by the addition of RGDS 
to megakaryocyte-fibroblast co-cultures (34).  Wickenhauser et al. also confirmed the 




interactions, as specific anti-CD41 monoclonal antibodies completely blocked fibroblast 
proliferation in megakaryocyte-fibroblast co-cultures (35).   
 
While all of these studies were performed in in vitro cultures, in total, these 
experiments provide substantial evidence that megakaryocytes play an important role in 
bone remodeling, directly affecting osteoblastic proliferation and function, osteoclast 
growth and development, and the expression of factors involved in both bone formation 
and resorption.  
 
While substantial evidence points to an overall anabolic effect of megakaryocytes, 
there remains conflicting evidence for a pro-catabolic influence of megakaryocytes on 
bone homeostasis as well.  While p45 NF-E2-deficient animals exhibit a clear increase in 
both bone mass osteoblast numbers, the quantity of osteoclasts is also increased.  These 
catabolic cells appear to exhibit normal functioning in vitro, which suggests that 
megakaryocytes also encourage osteoclast growth (7).  Megakaryocytes have been 
demonstrated to produce RANKL, which exerts a positive influence on osteoclast growth 
and function (19).  In addition, while one might expect that animals lacking normal 
functioning megakaryocyte would exhibit increased or more rapid-onset osteoporosis, 
mice deficient in platelet activating factor receptor develop only mild osteoporosis. 
Osteoclast survival in such mice is diminished; osteoclastic bone resorption is impaired 
(reviewed in (36).  In addition, the production of cytokines, such as IL-1, IL-6 and TNFα, 
also stimulates the production of RANKL by osteoblasts (37),, which promotes osteoclast 




destruction through the upregulation of factors such as RANKL also known as tumor 
necrosis factor-related activation-induced cytokine (TRANCE), the production of which, 
as the name suggests, can be upregulated by cytokines such as TNFα (18).  Overall, there 
is likely to be a highly complex interplay between megakaryocytes and the network of 
cells regulating bone formation and turnover.  
 
In this study, we have focused our efforts on the characterization of the contact-
dependant mechanism(s) by which megakaryocytes induce osteoblast 
proliferation/differentiation.  To this end, we have effectively neutralized several 
adhesion molecules known to function in the analogous interaction of megakaryocytes 
with fibroblasts.  Furthermore, we have explored the effect of interleukin (IL)-3 on our 
megakaryocyte-osteoblast model system.  These new data provide a new outlook on the 
mechanism(s) of megakaryocyte-osteoblast interactions and the role of this interplay in 





Statement of Purpose 
This study attempts to characterize the specific contact-dependent mechanisms by which 
megakaryocytes might induce osteoblast activation. To this end, we have selectively 
disrupted the function of several candidate cell surface proteins and examined the effect 
of said disruptions on megakaryocyte-induced enhancement of osteoblast proliferation in 
vitro as assayed by incorporation of a radio-labeled nucleotide. Furthermore, we examine 
the response of this model system to IL-3 as a potential mechanism of paracrine 
influence. 
 
Specific Aim 1: Assay megakaryocyte-induced osteoblast proliferation in the presence of 
EDTA, soluble RGDS tetrapeptide, and neutralizing antibodies against integrin 
α3 chain/CD49c, integrin α5 chain/CD49e, and glycoptotein (gp) IIb/integrin αIIb 
chain/CD41, respectively. This is intended to demonstrate the involvment of Ca-
dependent adhesion/signaling in general, RGD-binding receptors, and the relevant 
specific integrins, respectively.  
 
Specific Aim 2: Assay megakaryocyte-induced osteoblast proliferation in the presence of 
IL-3. This is intended to examine this cytokine as a potential mechanism of paracrine 





Materials and Methods  
 
Animals 
C57BL/6 mice were obtained from Jackson Labs (Bar Harbor, ME) and housed under 
standard conditions under a 12/12 hour light-dark cycle. Animals were allowed access to 
standard chow and water ad libitum.  
 
Primary osteoblast cultures 
C57BL/6 murine calvarial cells were prepared by sequential collagenase digestion 
(Worthington Biomedical) as previously described (38).  Three- to five-day-old mice 
were anesthetized by hypothermia and sacrificed by cervical decapitation. Calvariae 
isolated from these 3- to 5-day old C57BL/6 mice were treated with 4 mM ethyl 
disodium acetate (EDTA) in PBS for 10 minutes.  After repeating this treatment two 
additional times, samples were then subjected to sequential digestion with 200 U/ml 
CLS-2 bacterial collagenase (Worthington Biomedical Corp, Freehold, NJ) in PBS for 75 
minutes.  After the second 15 minutes period, the supernatant was harvested and 
designated fraction 1.  The solution was then replaced; after an additional 15 minutes, 
cells released during that time frame were designated fraction 2.  This was repeated three 
additional times, for a total of five fractions.  Fractions 1 and 2 were discarded; cells 
collected from fractions 3-5 were used as the starting population for OB/osteoprogenitor 
cultures.  After washing extensively in culture medium [α-Minimum Essential Media 




serum (HyClone, Logan, UT)], cells were plated at low density (approximately 2 x 104 
cells per ml; 2 x 103 per well in 96-well plates) and grown to confluence (typically 5-7 
days).  
 
Primary megakaryoctyte cultures  
C57BL/6 breeding pairs were set-up by placing four females and one male C57BL/6 
mouse in a cage together; the timing of pregnancies were determined by observing the 
presence of a mucus plug on female mice. At this point, the male mouse was removed, 
pregnant C57BL/6 mice were housed in individual cages, then sacrificed between 
embryonic days 13-15. Whole livers recovered from mouse fetuses at embryonic days 13 
and 15 were homogenized by successive passages through a 25-gauge needle to obtain a 
single cell suspension.  The resulting cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM, Life Technologies Inc., Gaithersburg, MD) supplemented with 
10% FCS (HyClone) and 1% conditioned medium (CM) from a murine thrombopoietin-
secreting fibroblast cell line.  After five days in culture, megakaryocytes were harvested 
by low-speed centrifugation at 400 rpm for 10 minutes, then overlayed on a 
discontinuous bovine serum albumin (BSA, Sigma) density gradient with consecutive 
layers of 0%, 1.5%, and 3.0% BSA dissolved in PBS.  Megakaryocytes were highly 
enriched in the cells that settled to the bottom within 40 minutes at 1 x gravity, making up 
more than 90% of the cells as determined by visual inspection and, in prior studies by 
FACS analysis.  Final cultures of megakaryocytes were collected by centrifugation and 
resuspended in α-Minimum Essential Medium (αMEM, Life Technologies Inc.) 







2x103  osteoblasts/well were co-cultured in the presence or absence of 5 x 103 
megakaryocytes/well in 96-well tissue culture plates. As negative controls, 5 x 103 
megakaryocytes/well were cultured alone. After four days in culture, 5-8 Ci/mmol 
tritiated (3H)-thymidine was added to each well to a final target concentration of 1 
µCi/well. After an additional 16 hours in culture, megakaryocytes, which are non-
adherent, were removed by extensive washing to ensure measurement of osteoblast 
proliferation alone (8). Osteoblast cultures were then frozen at -20°C until measurement, 
at which time cultures were thawed to 37°C and incorporated radioactivity was 
determined by scintiography. All experiments were performed in triplicate and averaged. 
Significant differences in tritium incorporation were determined by one-tailed Student’s 
T-test (p < 0.05).  
 
OB proliferation time course 
2 x 103 osteoblasts/well were cultured in the presence or absence of 5 x 103 
megakaryocytes/well in 96-well tissue culture plates. As negative controls, 5 x 103 
megakaryocytes/well were cultured alone. 3H-thymidine was added to cultures at 1, 2, 3, 






To determine if direct cell-cell contact was a requisite to megakarycyte induction of 
osteoblast proliferation, megakaryocytes and osteoblasts were cocultured while separated 
by a cell-impermeable membrane (pore sizes 0.1 or 0.4 µm, Corning) 3H-thymidine was 
added to the osteoblast cultures after 2 and 4 days. Tritium incorporation was assessed as 
described above.  
 
Integrin Inhibition  
The bivalent cation chelator ethylenediaminetetraacetic acid (EDTA, Sigma) was added 
to megakaryocyte-osteoblast co-cultures and osteoblast control cultures to examine the 
effect of non-selective integrin inhibition on megakaryocyte-induced osteoblast 
activation.  EDTA was added at low-dose (0.0125 mM) and high-dose (0.125 mM) 
quantities at the beginning of the four day culture period.  Control cultures were treated 
with vehicle alone (PBS).  EDTA remained in the culture medium throughout the 16-hour 
tritium incorporation under the culture conditions described above.  
 
As a subset of integrins bind to a conserved peptide sequence of Arg-Gly-Asp (RGD), we 
examined the effect of blockade of such receptors under the culture conditions described 
above.  To elucidate the involvement of RGD-binding receptors in our model system, the 
soluble tetrapeptide Arg-Gly-Asp-Ser (RGDS; Sigma) was titrated into co-cultures and 
osteoblast controls at a high dose (0.0625 mM) or low dose (0.0125 mM) at the 
beginning of a four-day culture period.  Controls were treated with vehicle alone (PBS). 
3H-thymidine was added as described above on the fourth day of culture; samples were 





Neutralizing Antibody Studies 
To determine the identity of those integrins functioning in the osteoblast- megakaryocyte 
interaction, we tested the effect of several neutralizing antibodies directed against specific 
adhesion molecules. The following antibodies were applied to co-cultures and osteoblast 
controls: integrin α3 chain/CD49c (10 µg/mL; polyclonal; R and D Systems), integrin α5 
chain/CD49e (20 µg/mL; clone: 5H10-27 MFR5; BD Pharmingen), and glycoptotein (gp) 
IIb/integrin αIIb chain/CD41 (10 ng/mL; clone: MWReg30; BD Pharmingen).  Goat IgG 
fraction was added to control cultures at equivalent concentrations to assure that blocking 
was antigen-specific.  After four days in culture, 1 µCi 3H-thymidine was added to each 
well; then cultures were incubated at 37ºC for an additional 16 hours, and tritium 
incorporation was measured by scintiography. 
 
IL-3-mediated proliferation  
To explore the effect of the cytokine IL-3 on megakaryocyte-induced osteoblast 
activation, recombinant murine IL-3 (R&D Systems) was titrated into co-cultures and 
controls at 0, 10, and 30 ng/mL.  After a four-day incubation, 3H-thymidine was added to 







Enhancement of osteoblast proliferation by co-culture with megakaryocytes 
 First, we confirmed the enhancement of osteoblast proliferation following co-
culture with megakaryocytes. Osteoblast proliferation was measured by tritium 
incorporation after 1, 2, 3, 4, and 5 days at 37ºC. In comparison to osteoblast cultured 
alone, co-culture with megakaryocytes enhanced osteoblast proliferation by 335% at five 
days (p=0.012; Figure 1A).  Minimal proliferation, which became detectable only after 
the five-day culture period, could be seen in the absence of megakaryocytes. As 
megakaryocytes are not adherent, the substantial washing performed prior to 
measurement of incorporated radioactivity should remove any megakaryocytes from 
cultures, ensuring that the detected signal was derived entirely from the contained 
osteoblasts.  The absence of any significant tritium incorporation in cultures of 
megakaryocytes alone confirmed the specificity of this assay, demonstrating that the 
increased radioactivity seen in osteoblast-megakaryocyte co-cultures was due to 
increased osteoblast proliferation in the presence of megakaryocytes.  
 
Requirement for cell-cell contact for MK enhancement of osteoblast growth 
The enhancement of osteoblast proliferation by megakaryocytes was dependent 
on direct cell-cell contact as the separation of these two cell types by a membrane 
abrogated the enhancement of osteoblast growth.  By measuring cell proliferation via 





Figure 1. Megakaryocytes induce osteoblast activation via contact-dependent 
mechansism(s). (A) Osteoblast prolifeferation increased more than three-fold by co-
culture with megakaryocytes for five days. (B) Proliferation was not enhanced, however, 




enhancement of osteoblast proliferation by co-culture with megakaryocytes over the 
levels seen by osteoblasts cultured alone. Separation of these two cell types in a transwell 
system, which allows free exchange of soluble factors, but prevents direct cell-cell 
contact, abrogated any enhancement of osteoblast growth.  Tritium incorporation in these 
cultures was not significantly different from osteoblasts cultured alone, again confirmed 
the requirement for a direct interaction between megakaryocytes and osteoblasts to 
stimulate ostoblast growth and function.  
 
Implication of Cell Adhesion in megakaryocyte-mediated osteoblast proliferation 
Integrins are cell surface adhesion molecules that have been implicated as 
candidate molecules involved in the contact-dependent enhancement of osteoblast 
proliferation and activity by megakaryocytes.  To interfere with the calcium-dependent 
interactions of integrins and their substrates, we utilized the bivalent cation chelator 
EDTA as a mechanism of inducing non-selective integrin inhibition in megakaryocyte-
osteoblast co-cultures.  EDTA was titrated into megakaryocyte-osteoblast co-cultures and 
osteoblast controls during a four-day culture period.  As measured by tritium 
incorporation during an additional 16-hour culture period, the addition of 12.5µM EDTA 
failed to inhibit megakaryocyte-induced activation. Incubation with 125µM EDTA 
significantly (p=0.048) reduced tritium incorporation in co-cultures by 18% without 
affecting osteoblast controls (Fig. 2A), suggesting that disruption of calcium-dependent 
protein-protein interactions abrogated the effect of megakaryocytes of osteoblast 
proliferation.  At higher concentrations tested, EDTA began  to  inhibit  osteoblast 






Figure 2.  Integrin involvement in MK-induced OB activation.  (A) 12.5µM EDTA was 
not sufficient to disrupt MK-induced OB proliferation, however 125µM EDTA 
diminished MK-induced proliferation by 18%. Tritium incorporation by OB 
monocultures was not affected at either concentration reported.  (B) Soluble tetrapeptide 
RGDS caused a dose-dependant inhibition of MK-induced proliferation with 12.5µM and 
62.5µM decreasing tritium incorporation in co-cultures by 26% and 50%, respectively.  





proliferation (data not shown), however, at the lower dose tested, the inhibition was 
specific to osteoblast-megakaryocyte co-cultures. 
 
Involvement of integrins in megakaryocyte-enhanced osteoblast growth 
 A subset of integrins bind to a conserved sequence composed of a Arg-Gly-Asp 
(RGD) binding sequence, including integrins α3 (CD49c), α5 (CD49e), and glycoptotein 
(gp) IIb/integrin αIIb chain (CD41). To elucidate the involvement of RGD-binding 
receptors in our model system, we titrated the soluble tetrapeptide Arg-Gly-Asp-Ser 
(RGDS; Sigma) into co-cultures  and  osteoblast  controls as  a  competitive  inhibitor  of  
these interactions.  RGDS caused a dramatic, dose-dependant inhibition of proliferation 
in co-cultures. Addition of 12.5µM and 62.5µM decreased megakaryocyte-induced 
activation in a dose-dependent manner, resulting in 26% (p=0.032) and 50% (p=0.014) 
reduction in osteoblast proliferation. RGDS had no effect on osteoblast control 
monocultures (Fig. 2B).  Further increases in RGDS concentration did not result in 
additional inhibition of proliferation in co-cultures.  These results support the hypothesis 
that RGD-binding integrins mediate the megakaryocte-dependent enhancement of 
osteoblast proliferation.  
 
Neutralization of specific adhesion molecules abrogated megakaryocyte 
enhancement of osteoblast growth 
To achieve more specific inhibition of cell adhesion molecules, we added 




cultures and osteoblast controls: integrin α3 chain/CD49c (10µg/mL), integrin α5 






Figure 3. Involvement of specific adhesion molecules in MK-induced OB activation.  
Application of neutralizing antibodies against integrin α3 chain (A), integrin α5 chain (B), 
and CD41 (C) each diminished MK-induced OB proliferation by approximately 20%, 





Goat IgG fraction was added to separate controls at equivalent concentrations to assure 
that blocking was antigen-specific.  Each of the neutralizing antibodies tested yielded 
virtually identical results, causing moderate reductions in co-culture proliferation without 
affecting osteoblast monocultures.  A maximal suppression of 21% (p=0.045) was seen 
with the addition of anti-α3 antibodies at 10µg/mL, 20% (p=0.023) with anti-
α5 antibodies at 20µg/mL, and 20% (p=0.036) by anti-CD41 antibodies at 10ng/mL (Fig. 
3).  Non-specific IgG did not affect tritium incorporation in co-cultures or osteoblast 
monocultures when added at respective control concentrations (data not shown).  These 
results implicated the involvement of fibronectin/RGD-binding integrins, including α3β1 
(VLA-3) and α5β1 (VLA-5) as well as glycoprotein IIb (CD41), all of which are known to 
be expressed on megakaryocyte membranes, in the cell contact-dependent interactions 
required for the megakaryocyte-mediated enhancement of osteoblast proliferation and 
function.   
 
IL-3 enhances megakaryocyte-mediated osteoblast proliferation 
Lastly, recombinant murine IL-3 (R and D Systems) was titrated into co-cultures 
and controls to explore the effect of this cytokine on megakaryocyte-induced osteoblast 
activation.  Finally, 10 ng/mL and 30 ng/mL IL-3 enhanced megakaryocyte-induced 
osteoblast proliferation by 41% (p=0.025) and 37% (p=0.034) respectively, while 
osteoblast monocultures remained unaffected (Fig. 4).  Further increasing IL-3 







Figure 4.  IL-3 enhances MK-induced OB activation.  At 10ng/mL and 30ng/mL, IL-3 
enhanced MK-induced OB proliferation by 41% and 37%, respectively.  Tritium 





 Our laboratory has previously demonstrated that megkaryocytes can induce 
osteoblast proliferation, but do so only when direct cell-to-cell contact is permitted (8) To 
further investigate the nature of this interaction, we have systematically disrupted known 
mechanisms of megakaryocyte-fibroblast adhesion/signaling in our megakaryocyte-
osteoblast co-culture model system.  We began our investigation with the addition of 
EDTA to co-cultures and controls.  This chelating agent reduces the availability of 
bivalent cations necessary for proper dimerization and ligand-binding of integrin 
heterodimers (41, 42) and has been shown to inhibit megakaryocyte-fibroblast adherence 
and signaling in vitro.(32).  The ability of EDTA to diminish megakaryocyte-induced 
osteoblast proliferation without affecting osteoblast monocultures thus implicates integrin 
involvement in megakaryocyte-osteoblast adherence/signaling.  Refining the scope of our 
investigation, we next examined the role of RGD-binding receptors in our model system.  
The conformation of the RGD sequence of fibronectin is approximated in a soluble form 
by the tetrapeptide RGDS (43), which serves to inhibit the interaction of fibronectin-
binding intergrins with their substrates.  Therefore, our finding that the addition of this 
tetrapeptide inhibits megakaryocyte-induced proliferation without affecting osteoblast 
monocultures implicates specifically, although not exclusively, RGD-binding integrins.  
These data are again consistent with those pertaining to megakaryocyte-fibroblast 
adherence/signaling (34).  The respective roles of megakaryocyte-expressed, fibronectin-
binding integrins α3β1 (VLA-3) and α5β1 (VLA-5; an RGD receptor integrin) were then 
examined by application of neutralizing antibodies to co-cultures and controls. This 




mono-cultures were not affected by these antibodies, and non-specific IgG affected 
neither co-cultures nor osteoblast controls, we conclude that these specific integrins 
directly contribute to megakaryocyte-osteoblast adhesion/activation, as demonstrated in 
the megakaryocyte-fibroblast model system (34).  Employing the same technique and 
reasoning, we next elucidated the involvement of the megakaryocyte-expressed 
glycoprotein CD41.  This molecule, also known as gpIIb, is retained on the surfaces of 
mature platelets where it complexes with CD61 (gpIIIa) forming a heterodimeric receptor 
capable of recognizing a host of extracellular proteins (fibrinogen, fibronectin, von 
Willebrand factor, vitronectin, etc.) with affinities modulated by the state of platelet 
activation.  In agreement with megakaryocyte-fibroblast interaction findings (35)  we 
conclude that this glycoprotein also plays an important role in megakaryocyte-induced 
adherence/activation. 
 
 Lastly, our data demonstrate that IL-3 significantly enhances megakaryocyte-
induced osteoblast proliferation without affecting osteoblast monocultures.  Although we 
have not demonstrated that this enhancement is contingent upon direct cell-cell contact, 
Schmitz et al. (32) showed that IL-3 could not enhance fibroblast proliferation when 
megakaryocyte-fibroblast co-cultures were divided by cell-impermeable membranes.  
Furthermore, the prerequisite of direct cell-cell contact in no way excludes an additive 
effect of signaling via soluble factors as a mechanism for megakaryocyte-induced 
mesenchymal cell activation.  To the contrary, Schmitz et al. (32) speculate that adhesion 
may serve principally to expose fibroblasts to supra-threshold levels of megakaryocyte-




a series of real-time PCR studies on IL-3-treated versus untreated megakaryocytes to 
explore these and other possibilities.  While many such details of our own model - and 
skeletal homeostasis in general - remain obscure, we propose the following model of 
skeletal homeostasis, in which a complex network of both direct and indirect interactions 
between megakaryocytes and osteoblasts control bone homeostasis (Figure 5). 
Megakaryocytes induce osteoblast proliferation/differentiation via a contact-dependant 
mechanism(s), characterization of which is the subject of this investigation.  While 
additional factors may contribute, the fibronectin-binding integrins α3β1 (VLA-3) and 
α5β1 (VLA-5) and the gpIIb (CD41)/gpIIIa (CD61) heterodimer function to increase 
osteoblast proliferation and differentiation through direct cell-cell interactions.  Cytokines 
produced by megakaryocytes act indirectly on osteoblasts to promote bone growth, both 
by enhancing osteoblast proliferation and by increasing the deposition of matrix proteins, 
such as collagen and osteocalcin.  Megakaryocytes also elaborate an unidentified soluble 
factor(s) of 10-50kDa (red) which inhibits osteoclast formation.  Megakaryocytopoiesis is 
promoted by thrombopoietin, which is produced within the marrow space by 
osteoblast/stromal cells.  The stimulation of megakaryocytopoiesis by thrombopoietin 
enhances the production of cytokines by megakaryocytes, which act in a positive 
feedback manner to enhance megakaryocyte differentiation additively.  Lastly, 
osteoblasts induce osteoclast formation via RANK/RANK-ligand interaction. 
Megakaryocyte may also contribute to increased osteoclast differentiation and function 
through elaboration of proteins such as RANKL.  Estrogen, deficiency in which produces 




increase the production of osteoblast growth factors by megakaryocytes, again 




Figure 5.  The evolving role of MKs in skeletal homeostasis.  MKs induce OB 
proliferation/differentiation via a contact-dependant mechanism(s) (yellow), 
characterization of which is the subject of this investigation.  MKs also elaborate an 
unidentified soluble factor(s) of 10-50kDa (red) which inhibits OC formation.  
Megakaryopoiesis is promoted by thrombopoietin (TPO; green) elaborated within the 
marrow space by OB/stromal cells.  Lastly, OBs induce OC formation via 







Multiple studies in vitro and in mutant mice demonstrate that the bone density 
correlates well with the overall numbers of megakaryocytes and the amount of 
megakaryocytopoiesis.  GATA-1- and NF-E2-deficient mice possess increased numbers 
of megakaryocytes, which correlates with excessive bone formation (8). Thrombopoietin, 
a megakaryocyte-specific growth factor that is the primary stimulator of 
megakaryocytopoiesis in vivo, exerts a substantial effect on bone homeostasis through 
direct modification of megakaryocyte growth and activity.  The receptor for 
thrombopoietin, c-Mpl, is constitutively expressed by megakaryocytes at all stages of 
development and can be upregulated by thrombopoietin stimulation.  The receptor then 
undergoes a conformational change to initiate signal transduction through via Janus 
kinase (JAK) family kinases that are constitutively bound to the cytoplasmic tail of c-
Mpl. Activated JAK in turn phosphorylates the receptor and other signaling molecules, 
such as signal transducers and activators of transcription (STATs), phosphoinositide-3-
kinase (PI3K) and mitogen-activated protein kinases (MAPKs), eventually resulting in 
the activation of the transcriptional regulators GATA-1 and NF-E2 that are key 
controllers of megakaryocyte-specific gene expression.  These signaling pathways lead to 
cell survival and proliferation as well as the stimulation of cytokine production.  
Eventually, kinase activity activates the SHP1 and SHIP1 phosphatases as well as 
suppressors of cytokine signaling (SOCSs) to terminate cell signaling (reviewed in 
reviewed in 44.).  While the signal transduction molecules functioning downstream of 




multiple important cell surface receptors, both the downstream transcriptional regulators 
(GATA-1 and NF-E2) and initiators of transcription (thrombopoietin, c-Mpl) appear to 
function relatively specifically in megakaryocytopoiesis, making these proteins good 
potential sites for therapeutic manipulation.  While inhibition or enhancement of 
megakaryocytopoiesis might have the desired effect on bone homeostasis, it would also 
have undesirable effects on hemostasis, leading to either thrombocytopenia and resultant 
bleeding or thrombocytosis and possible myelofibrosis, significant complications with 
profound sequelae.  
 
Megakaryocytes appear to exert their effects on osteoblasts via both direct 
intracellular interactions and indirect paracrine manipulation. Our studies implicate the 
megakaryocyte-expressed, fibronectin-binding integrins α3β1 (VLA-3) and α5β1 (VLA-5; 
an RGD receptor integrin) and the gpIIb (CD41)/gpIIIa (CD61) heterodimer as critical 
cell surface molecules on megakaryocytes mediating the cell-cell contacts functioning to 
enhance osteoblast growth and function.  Although these cell adhesion molecules also 
function in multiple cellular systems throughout the body, it has been proposed that cell 
adhesion in the interactions of megakaryocytes with osteobalsts may serve only to 
facilitate localized secretion of soluble mediators, resulting in an increased local 
concentration of paracrine factors that exceeds the cellular threshold required for 
activation (25) If this hypothesis is true, it may be possible to facilitate cell-cell 
interactions with the rational design of bivalent agents that interact with cell surface 




follows.  Such an approach is as yet hypothetical, but could be attempted with minimal 
effects on other organ systems.  
 
Megakaryocytes also influence osteoblast activity through the elaboration of 
multiple soluble factors, both autocrine, such as IL-3 and IL-6, and paracrine factors, 
including osteoprotegerin, osteocalcin, and osteonectin. We have specifically 
demonstrated the importance of IL-3 as a key upstream regulator in this process, Given 
the role of interleukins in multiple tissues, as in the immune system, treatment with 
exogenous cytokines could have substantial undesirable systemic side effects.  Thus, it 
would be more desirable to attempt manipulation of more bone-specific factors.  
Osteoprotegerin is a central regulator of bone homeostasis, maintaining the careful 
balance between bone anabolism and catabolism. Manipulation of the production of some 
of these soluble, bone-specific proteins produced by megakaryocytes might be sufficient 
to increase bone density without interfering with platelet production or function, allowing 
for the selective treatment of osteoporosis and other diseases of bone loss. 
 
Estrogens have also been shown to influence megakaryocytes and the regulation 
of bone homeostasis by megakaryocytes.  While estrogen replacement is an effective 
treatment for osteoporosis associated with reductions in endogenous hormone levels, this 
treatment is administered with caution due to the unfortunately side effects that include 
an increased incidence of certain cancers and increased heart disease in certain 
individuals.  A better understanding of the mechanisms by which estrogens influence 




these pathways selectively, resulting in effective treatment for osteoporosis and reduced 
systemic side effects.  
 
While the fine details of the molecular mechanisms governing the regulation of 
bone homeostasis by megakaryocytes remain unclear, these studies could have a 
significant impact on the treatment of disease of decreased bone mass, such as 
osteoporosis. The identification of the pathways and substrates on bone stromal cells 
functioning in the regulation of osteoclast and osteoblast function by megakaryocytes has 
identified new potential targets that may be manipulated pharmacologically in the 
treatment of bone diseases. In addition, better understanding of the soluble molecules 
produced by megakaryocytes to regulate bone homeostasis provides us with starting 
points for the rational design of drugs that could be used to manipulate any abnormalities 
of bone, from osteopenia and the lytic bone destruction of multiple myeloma to the 
excessive bone production seen in diseases such as Paget’s disease.  While significant 
research still remains before we can manipulate these pathways with ease, we remain 
ambitious that our efforts will contribute to a higher standard of clinical care for 
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